Pediatric Myocarditis: What Have We Learnt So Far?

被引:8
|
作者
Pomiato, Elettra [1 ]
Perrone, Marco Alfonso [1 ]
Palmieri, Rosalinda [1 ]
Gagliardi, Maria Giulia [1 ]
机构
[1] Bambino Gesu Pediat Hosp, Dept Pediat Cardiol & Cardiac Surg, IRCCS, I-00165 Rome, Italy
关键词
myocarditis; children; endomyocardial biopsy; inflammatory cardiomyopathy; immune system; GIANT-CELL MYOCARDITIS; CARDIOVASCULAR MAGNETIC-RESONANCE; ENDOMYOCARDIAL BIOPSY; FOLLOW-UP; DILATED CARDIOMYOPATHY; UNITED-STATES; IMMUNOSUPPRESSIVE THERAPY; CLINICAL PRESENTATION; CIRCULATORY SUPPORT; REPAIRED TETRALOGY;
D O I
10.3390/jcdd9050143
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myocarditis is an inflammatory disease of the myocardium that is troublesome to diagnose and manage, especially in children. Since the introduction of endomyocardial biopsy (EMB), new diagnostic tools have provided useful data. Especially when enhanced with immunohistochemistry and polymerase chain reaction (PCR) studies, EMB remains the gold standard for the diagnosis. Notably, cardiac magnetic resonance (MRI) is a non-invasive tool that can confirm the diagnosis and has a particular usefulness during the follow-up. The causes of myocarditis are heterogeneous (mostly viral in children). The course and outcome of the illness in the pediatric population represent a complex interaction between etiologic agents and the immune system, which is still not fully understood. The clinical presentation and course of myocarditis vary widely from paucisymptomatic illness to acute heart failure refractory to therapy, arrhythmias, angina-like presentation and sudden cardiac death. In this setting, cardiac biomarkers (i.e., troponins and BNP), although unspecific, can be used to support the diagnosis. Finally, the efficacy of therapeutic strategies is controversial and not confirmed by clinical trials. In this review, we summarized the milestones in diagnosis and provided an overview of the therapeutic options for myocarditis in children.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] BioBank Japan and what we have learnt so far
    Okada, Yukinori
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 84 - 85
  • [2] Proteomics in aortic aneurysm - What have we learnt so far?
    Abdulkareem, Nada
    Skroblin, Philipp
    Jahangiri, Marjan
    Mayr, Manuel
    [J]. PROTEOMICS CLINICAL APPLICATIONS, 2013, 7 (7-8) : 504 - 515
  • [3] Central serous chorioretinopathy: what we have learnt so far
    Wong, Kah Hie
    Lau, Kin Pong
    Chhablani, Jay
    Tao, Yong
    Li, Qing
    Wong, Ian Y.
    [J]. ACTA OPHTHALMOLOGICA, 2016, 94 (04) : 321 - 325
  • [4] Animal Models for Dysphagia Studies: What Have We Learnt So Far
    German, Rebecca Z.
    Crompton, A. W.
    Gould, Francois D. H.
    Thexton, Allan J.
    [J]. DYSPHAGIA, 2017, 32 (01) : 73 - 77
  • [5] Editorial: Cancer Epidemiology in China: What We Have Learnt So Far?
    Chen, Tianhui
    Shu, Xiaochen
    Liu, Hao
    Ji, Jianguang
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] INVOLVING OLDER PEOPLE IN RESEARCH: WHAT HAVE WE LEARNT SO FAR?
    Phillips, J. E.
    [J]. GERONTOLOGIST, 2009, 49 : 303 - 303
  • [7] What have we learnt so far from COVID-19?
    Doherty, Peter C.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2021, 21 (02) : 67 - 68
  • [8] Animal Models for Dysphagia Studies: What Have We Learnt So Far
    Rebecca Z. German
    A. W. Crompton
    Francois D. H. Gould
    Allan J. Thexton
    [J]. Dysphagia, 2017, 32 : 73 - 77
  • [9] What have we learnt so far from COVID-19?
    Peter C. Doherty
    [J]. Nature Reviews Immunology, 2021, 21 : 67 - 68
  • [10] International Labour Regulation: What Have We Really Learnt So Far?
    Tsogas, George
    [J]. RELATIONS INDUSTRIELLES-INDUSTRIAL RELATIONS, 2009, 64 (01): : 75 - 94